Bolt Biotherapeutics, Inc. Financials
This page shows Bolt Biotherapeutics, Inc. (BOLT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Bolt Biotherapeutics, Inc. has an operating margin of -469.3%, meaning the company retains $-469 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -949.9% the prior year.
Bolt Biotherapeutics, Inc.'s revenue grew a modest 0.1% year-over-year to $7.7M. This slow but positive growth earns a score of 33/100.
Bolt Biotherapeutics, Inc. carries a low D/E ratio of 1.14, meaning only $1.14 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 79/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 3.59, Bolt Biotherapeutics, Inc. holds $3.59 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 70/100.
While Bolt Biotherapeutics, Inc. generated -$39.9M in operating cash flow, capex of $72K consumed most of it, leaving -$39.9M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Bolt Biotherapeutics, Inc. generates a -125.9% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -110.3% the prior year.
Bolt Biotherapeutics, Inc. passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Bolt Biotherapeutics, Inc. generates $1.19 in operating cash flow (-$39.9M OCF vs -$33.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Bolt Biotherapeutics, Inc. generated $7.7M in revenue in fiscal year 2025. This represents an increase of 0.1% from the prior year.
Bolt Biotherapeutics, Inc.'s EBITDA was -$34.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 51.1% from the prior year.
Bolt Biotherapeutics, Inc. reported -$33.4M in net income in fiscal year 2025. This represents an increase of 47.1% from the prior year.
Bolt Biotherapeutics, Inc. earned $-17.85 per diluted share (EPS) in fiscal year 2025. This represents an increase of 46.0% from the prior year.
Cash & Balance Sheet
Bolt Biotherapeutics, Inc. generated -$39.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 34.9% from the prior year.
Bolt Biotherapeutics, Inc. held $11.7M in cash against $0 in long-term debt as of fiscal year 2025.
Bolt Biotherapeutics, Inc. had 2M shares outstanding in fiscal year 2025. This represents an increase of 0.2% from the prior year.
Margins & Returns
Bolt Biotherapeutics, Inc.'s operating margin was -469.3% in fiscal year 2025, reflecting core business profitability. This is up 480.6 percentage points from the prior year.
Bolt Biotherapeutics, Inc.'s net profit margin was -433.7% in fiscal year 2025, showing the share of revenue converted to profit. This is up 387.0 percentage points from the prior year.
Bolt Biotherapeutics, Inc.'s ROE was -125.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 15.6 percentage points from the prior year.
Capital Allocation
Bolt Biotherapeutics, Inc. invested $28.5M in research and development in fiscal year 2025. This represents a decrease of 50.4% from the prior year.
Bolt Biotherapeutics, Inc. invested $72K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 75.6% from the prior year.
BOLT Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5M+15.3% | $2.2M+20.2% | $1.8M+47.6% | $1.2M | $0-100.0% | $1.1M-10.5% | $1.3M-75.8% | $5.3M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $5.0M-23.7% | $6.5M-12.8% | $7.5M-21.2% | $9.5M-18.9% | $11.7M-15.0% | $13.8M-10.7% | $15.4M-6.6% | $16.5M |
| SG&A Expenses | $3.1M-6.6% | $3.3M-5.1% | $3.5M-8.1% | $3.8M-3.1% | $3.9M+3.9% | $3.8M-22.1% | $4.9M-16.5% | $5.8M |
| Operating Income | -$7.1M+8.0% | -$7.7M+16.4% | -$9.2M+24.0% | -$12.1M+28.4% | -$16.9M-2.9% | -$16.4M+27.2% | -$22.6M-32.2% | -$17.1M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$6.6M+7.2% | -$7.1M+16.6% | -$8.6M+22.5% | -$11.0M+30.7% | -$15.9M-5.0% | -$15.2M+28.4% | -$21.2M-96.1% | -$10.8M |
| EPS (Diluted) | N/A | $-3.72+16.6% | $-4.46 | $-0.29 | N/A | $-7.93+28.7% | $-11.12-3871.4% | $-0.28 |
BOLT Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $56.7M-12.8% | $65.1M-13.8% | $75.5M-12.1% | $85.9M-13.8% | $99.6M-8.9% | $109.3M-12.0% | $124.2M-13.1% | $142.9M |
| Current Assets | $30.3M-15.0% | $35.6M-7.1% | $38.3M-9.8% | $42.5M-16.3% | $50.8M-11.1% | $57.1M-25.4% | $76.6M-19.4% | $95.1M |
| Cash & Equivalents | $11.7M-34.1% | $17.8M+84.9% | $9.6M+14.4% | $8.4M+16.5% | $7.2M-23.1% | $9.4M+51.0% | $6.2M+45.5% | $4.3M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $30.2M-8.2% | $33.0M-10.1% | $36.7M-6.1% | $39.1M-8.0% | $42.4M+13.8% | $37.3M-2.6% | $38.3M-1.1% | $38.7M |
| Current Liabilities | $8.4M-15.4% | $10.0M-19.0% | $12.3M-9.2% | $13.6M-14.5% | $15.9M-12.3% | $18.1M+1.0% | $17.9M+7.0% | $16.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $26.5M-17.4% | $32.1M-17.4% | $38.8M-17.0% | $46.8M-18.2% | $57.2M-20.6% | $72.0M-16.1% | $85.9M-17.6% | $104.2M |
| Retained Earnings | -$460.8M-1.5% | -$454.1M-1.6% | -$447.0M-2.0% | -$438.4M-2.6% | -$427.4M-3.9% | -$411.5M-3.8% | -$396.3M-5.7% | -$375.1M |
BOLT Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.2M+26.5% | -$9.7M-1.4% | -$9.6M+28.2% | -$13.4M+7.4% | -$14.4M-3.3% | -$14.0M+13.5% | -$16.1M+3.6% | -$16.8M |
| Capital Expenditures | $0 | N/A | N/A | N/A | $0-100.0% | $41K | $0 | $0 |
| Free Cash Flow | -$7.2M | N/A | N/A | N/A | -$14.4M-3.0% | -$14.0M+13.2% | -$16.1M+3.6% | -$16.8M |
| Investing Cash Flow | $1.1M-94.0% | $17.9M+65.7% | $10.8M-25.8% | $14.6M+19.0% | $12.2M-28.6% | $17.1M-4.8% | $18.0M+76.4% | $10.2M |
| Financing Cash Flow | $5K | $0-100.0% | $14K | $0-100.0% | $29K | $0-100.0% | $79K | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BOLT Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -283.4%+71.7pp | -355.1%+155.4pp | -510.5%+480.9pp | -991.4% | N/A | -1441.1%+331.2pp | -1772.3%-1448.2pp | -324.1% |
| Net Margin | -265.2%+64.1pp | -329.4%+145.2pp | -474.6%+428.9pp | -903.4% | N/A | -1330.1%+332.3pp | -1662.3%-1457.4pp | -205.0% |
| Return on Equity | -25.0%-2.8pp | -22.3%-0.2pp | -22.0%+1.5pp | -23.6%+4.3pp | -27.9%-6.8pp | -21.1%+3.6pp | -24.7%-14.3pp | -10.4% |
| Return on Assets | -11.7%-0.7pp | -11.0%+0.4pp | -11.3%+1.5pp | -12.9%+3.1pp | -16.0%-2.1pp | -13.9%+3.2pp | -17.1%-9.5pp | -7.6% |
| Current Ratio | 3.59+0.0 | 3.57+0.5 | 3.11-0.0 | 3.13-0.1 | 3.20+0.0 | 3.16-1.1 | 4.28-1.4 | 5.68 |
| Debt-to-Equity | 1.14+0.1 | 1.03+0.1 | 0.94+0.1 | 0.83+0.1 | 0.74+0.2 | 0.52+0.1 | 0.45+0.1 | 0.37 |
| FCF Margin | -286.2% | N/A | N/A | N/A | N/A | -1227.6%+38.4pp | -1266.0%-948.4pp | -317.6% |
Similar Companies
Frequently Asked Questions
What is Bolt Biotherapeutics, Inc.'s annual revenue?
Bolt Biotherapeutics, Inc. (BOLT) reported $7.7M in total revenue for fiscal year 2025. This represents a 0.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Bolt Biotherapeutics, Inc.'s revenue growing?
Bolt Biotherapeutics, Inc. (BOLT) revenue grew by 0.1% year-over-year, from $7.7M to $7.7M in fiscal year 2025.
Is Bolt Biotherapeutics, Inc. profitable?
No, Bolt Biotherapeutics, Inc. (BOLT) reported a net income of -$33.4M in fiscal year 2025, with a net profit margin of -433.7%.
What is Bolt Biotherapeutics, Inc.'s EBITDA?
Bolt Biotherapeutics, Inc. (BOLT) had EBITDA of -$34.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Bolt Biotherapeutics, Inc.'s operating margin?
Bolt Biotherapeutics, Inc. (BOLT) had an operating margin of -469.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Bolt Biotherapeutics, Inc.'s net profit margin?
Bolt Biotherapeutics, Inc. (BOLT) had a net profit margin of -433.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Bolt Biotherapeutics, Inc.'s return on equity (ROE)?
Bolt Biotherapeutics, Inc. (BOLT) has a return on equity of -125.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Bolt Biotherapeutics, Inc.'s free cash flow?
Bolt Biotherapeutics, Inc. (BOLT) generated -$39.9M in free cash flow during fiscal year 2025. This represents a 34.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Bolt Biotherapeutics, Inc.'s operating cash flow?
Bolt Biotherapeutics, Inc. (BOLT) generated -$39.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Bolt Biotherapeutics, Inc.'s total assets?
Bolt Biotherapeutics, Inc. (BOLT) had $56.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Bolt Biotherapeutics, Inc.'s capital expenditures?
Bolt Biotherapeutics, Inc. (BOLT) invested $72K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Bolt Biotherapeutics, Inc. spend on research and development?
Bolt Biotherapeutics, Inc. (BOLT) invested $28.5M in research and development during fiscal year 2025.
What is Bolt Biotherapeutics, Inc.'s current ratio?
Bolt Biotherapeutics, Inc. (BOLT) had a current ratio of 3.59 as of fiscal year 2025, which is generally considered healthy.
What is Bolt Biotherapeutics, Inc.'s debt-to-equity ratio?
Bolt Biotherapeutics, Inc. (BOLT) had a debt-to-equity ratio of 1.14 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Bolt Biotherapeutics, Inc.'s return on assets (ROA)?
Bolt Biotherapeutics, Inc. (BOLT) had a return on assets of -58.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Bolt Biotherapeutics, Inc.'s cash runway?
Based on fiscal year 2025 data, Bolt Biotherapeutics, Inc. (BOLT) had $11.7M in cash against an annual operating cash burn of $39.9M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Bolt Biotherapeutics, Inc.'s Piotroski F-Score?
Bolt Biotherapeutics, Inc. (BOLT) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Bolt Biotherapeutics, Inc.'s earnings high quality?
Bolt Biotherapeutics, Inc. (BOLT) has an earnings quality ratio of 1.19x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Bolt Biotherapeutics, Inc.?
Bolt Biotherapeutics, Inc. (BOLT) scores 30 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.